Bao-Dong Qin

Bao-Dong Qin

Auto-generated profile, based on publicly available information

Bao-Dong Qin

Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
BQBao-Dong Qin
Bao-Dong Qin
XJXiao-Dong Jiao
Xiao-Dong Jiao
JLJun Liu
Jun Liu
KLKe Liu
Ke Liu
XHXi He
Xi He
YZYuansheng Zang
Yuansheng Zang

16 April 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
BQBao-Dong Qin
Bao-Dong Qin
XJXiao-Dong Jiao
Xiao-Dong Jiao
LYLing-Yan Yuan
Ling-Yan Yuan
YWYing Wu
Ying Wu
YLYan Ling
Yan Ling
YZYuansheng Zang
Yuansheng Zang
The sustained benefit of immunotherapy-based regimens in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) failure is debatable. Neither Checkmate-722 nor Keynote-789 reached the prespecified statistical level of clinical benefit, but the ORIENT-31 and ATTLAS trials showed that the addition of a VEGF inhibitor to immunotherapy plus chemotherapy could significantly prolong survival. However, head-to-head comparisons of the efficacy of immunotherapy plus bevacizumab with chemotherapy versus that of immunotherapy with chemotherapy in this patient population are lacking. In addition, the critical question of who would benefit from an immunotherapy-based regimen remains unclear. We conducted an indirect comparative meta-analysis using chemotherapy as a common comparator to classify the relative efficacy of the two immunotherapy-based regimens. The indirect comparison showed that immunotherapy and bevacizumab plus chemotherapy had a significantly better progression-free survival (PFS) (HRIO+Bev+Chemo/IO+Chemo=0.71, 95% CI 0.55 to 0.91) than immunotherapy plus chemotherapy. The EGFR mutation type and T790M mutation were found to be significantly associated with PFS of immunotherapy-based regimens. Compared with their counterparts, patients with L858R (HR 0.52, 95%CI 0.37 to 0.72), without T790M mutation (HR 0.50, 95% CI 0.35 to 0.71) tended to benefit significantly more from immunotherapy-based regimens. In conclusion, our findings support that the addition of VEGF inhibitor to immunotherapy and chemotherapy could be the preferred option for TKI-resistant, EGFR-mutated NSCLC, and that L858R mutation and T790M negativity could be identified as efficacy-associated factors for immunotherapy-based regimens.

21 January 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
ZWZhan Wang
Zhan Wang
BQBao-Dong Qin
Bao-Dong Qin
CYChen-Yang Ye
Chen-Yang Ye
MWMiao-Miao Wang
Miao-Miao Wang
LYLing-Yan Yuan
Ling-Yan Yuan
YZYuansheng Zang
Yuansheng Zang

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Open access
XHXi He
Xi He
XJXiao-Dong Jiao
Xiao-Dong Jiao
KLKe Liu
Ke Liu
BQBao-Dong Qin
Bao-Dong Qin
YWYing Wu
Ying Wu
YZYuansheng Zang
Yuansheng Zang

8 May 2023 in International Journal of Cancer
Verified
Journal Article
Closed access
BQBao‐Dong Qin
Bao‐Dong Qin
XJXiao‐Dong Jiao
Xiao‐Dong Jiao
ZWZhan Wang
Zhan Wang
KLKe Liu
Ke Liu
YWYing Wu
Ying Wu
YZYuan‐Sheng Zang
Yuan‐Sheng Zang

1 January 2025 in Cancer Control
Verified
Journal Article
Open access
JHJia-Jun Hui
Jia-Jun Hui
HYHan-Lu Yan
Han-Lu Yan
SDSheng-Jun Ding
Sheng-Jun Ding
BQBao-Dong Qin
Bao-Dong Qin
XJXiao-Dong Jiao
Xiao-Dong Jiao
YZYuansheng Zang
Yuansheng Zang
Background: This cohort study aimed to evaluate the impact of tumor burden (TB) on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). Materials and Methods: Data from the POPLAR and OAK trials were extracted as the training and validation cohorts, respectively. TB was defined as the sum of the longest dimensions (blSLD) of measurable target lesions as per RECIST v1.1. The Kaplan-Meier curves and multivariate Cox regression analyses were performed to assess the association between TB with blood-tested tumor mutation burden (bTMB), PD-L1 expression, and survival outcomes. Additionally, random forest algorithms analysis was performed to evaluate the accuracy of TB in predicting 12-month mortality of NSCLC patients received atezolizumab. Results: A total of 105 patients from the POPLAR trial and 322 patients from the OAK trial were recruited in the training and validation sets, respectively. Patients with TB-L have significantly better OS than those with TB-H in the training (mOS: 15.8 months vs 6.93 months) as well as the validation (mOS: 16.0 months vs 7.59 months) cohort. The multivariate Cox regression analysis indicated that TB is an independent biomarker for OS prediction, regardless of bTMB, PD-L1 expression, and number of metastasis sites. The impact of TB on 12-month mortality was expected to be stronger with the increase of TB, suggesting that patients with a high tumor burden experienced a detrimental effect on 12-month mortality. Conclusion: TB may act as a prognostic biomarker for clinical benefit in NSCLC patients treated with immunotherapy alone. This may be potentially effective for predicting the efficacy of immunotherapy-based regimens.